Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Jun 24, 2024 12:23pm
158 Views
Post# 36103436

RE:RE:RE:RE:RE:RE:RE:Dr Matt medical leave

RE:RE:RE:RE:RE:RE:RE:Dr Matt medical leave

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by or on behalf of the following persons in the capacities indicated on June 3, 2024:

 

Signature   Title
 
/s/ Matthew Coffey   President, Chief Executive Officer and
Matthew C. Coffey   Chairman of the Board
(Principal Executive Officer)
 
/s/ Kirk Look   Chief Financial Officer and Director
Kirk Look   (Principal Financial and Accounting Officer)
 
/s/ James T. Parsons   Director
James T. Parsons    
 
/s/ Deborah M. Brown   Director
Deborah M. Brown    
 
/s/ Angela Holtman   Director
Angela Holtham    
 
/s/ Wayne Pisano   Director
Wayne Pisano    
 
/s/ Jonathan Rigby   Director
Jonathan Rigby    
     
/s/ Patricia Andrews   Director
Patricia Andrews    
     
/s/ Bernd R. Seizinger   Director
Bernd. R. Seizinger    

<< Previous
Bullboard Posts
Next >>